Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fan Hsu

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Human Mutation|February 28, 2007
PhenCode: connecting ENCODE data with mutations and phenotypeBelinda Giardine, Cathy Riemer, Tim Hefferon, et al.
Nucleic Acids Research|November 13, 2009
The UCSC Genome Browser database: update 2010Brooke Rhead, Donna Karolchik, Robert M Kuhn, et al.
Nucleic Acids Research|October 21, 2010
The UCSC Genome Browser database: update 2011Pauline A Fujita, Brooke Rhead, Ann S Zweig, et al.
Nucleic Acids Research|November 17, 2011
The UCSC Genome Browser database: extensions and updates 2011Timothy R Dreszer, Donna Karolchik, Ann S Zweig, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Nucleic Acids Research|November 17, 2012
The UCSC Genome Browser database: extensions and updates 2013Laurence R Meyer, Ann S Zweig, Angie S Hinrichs, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Human Mutation|February 28, 2007
PhenCode: connecting ENCODE data with mutations and phenotypeBelinda Giardine, Cathy Riemer, Tim Hefferon, et al.
Nucleic Acids Research|November 13, 2009
The UCSC Genome Browser database: update 2010Brooke Rhead, Donna Karolchik, Robert M Kuhn, et al.
Nucleic Acids Research|October 21, 2010
The UCSC Genome Browser database: update 2011Pauline A Fujita, Brooke Rhead, Ann S Zweig, et al.
Nucleic Acids Research|November 17, 2011
The UCSC Genome Browser database: extensions and updates 2011Timothy R Dreszer, Donna Karolchik, Ann S Zweig, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Nucleic Acids Research|November 17, 2012
The UCSC Genome Browser database: extensions and updates 2013Laurence R Meyer, Ann S Zweig, Angie S Hinrichs, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Pageof 12